Navigation Links
US Oncology Pharmaceutical Distribution Service Wins National Safety Council Award

HOUSTON, Sept. 3 /PRNewswire/ -- US Oncology Specialty, LP, the state-of-the-art pharmaceutical distribution center of US Oncology, has received the Occupational Excellence Achievement Award from the National Safety Council for its outstanding safety achievements.

The award is presented to companies who produce the "best of the best" in safety and safety performance. To be eligible, organizations must report days away from work resulting from workplace injuries or illness at a rate equal to or less than 50 percent of the Bureau of Labor Statistics (BLS) rate for their classification code. The BLS rate for US Oncology Specialty's classification code is 0.9 percent; in order to qualify the organization had to report an incident rate of .45 percent or lower. In 2007, US Oncology Specialty, employing 32 employees, achieved a lost workday incidence rate of zero percent.

US Oncology Specialty was launched in 2005 to manage the ordering and delivery of approximately $1.8 billion of pharmaceuticals each year for its affiliated network of community-based oncologists. The organization has focused on ensuring the protection of employees and patients by investing in systems and security measures that produce results. The industry-leading distribution service was the first oncology distributor to achieve the National Association of Boards of Pharmacy's (NABP) Verified-Accredited Wholesale Distributors (VAWD) accreditation to implement electronic pedigree technology, ensuring that pharmaceuticals are securely tracked, from the manufacturer to the patient, for optimum security and safety.

Additionally, the organization has twice received the Occupational Excellence Award from the Texas chapter of the National Safety Council.

About US Oncology, Inc.

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology's expertise in supporting every aspect of the cancer care delivery system -- from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,247 physicians operating in 472 locations, including 91 radiation oncology facilities in 39 states. For more information, visit the company's Web site,

SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
2. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
3. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
4. US Oncology to Report 2008 Second Quarter Earnings Results
5. Texas Oncology-Baylor Sammons Cancer Center Recognized for Highest Commitment to Clinical Research at ASCO
6. US Oncology Manufacturing-Inspired Practice Management Model Producing Quality and Efficiency Improvements
7. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
8. ACORN Expands Oncology Information Portfolio With Comprehensive Data Warehouse
9. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
10. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
11. EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):